Dapirolizumab pegol is an investigational Fc-free polyethylene glycol-conjugated antigen-binding fragment that inhibits CD40 ligand signaling.

A discussion of the use of beta-blocker therapy following AMI, with Christopher Granger, MD, Gregg Fonarow, MD, and Carlin S Long, MD.

Another health care worker who was exposed to a Missouri patient who tested positive for bird flu developed respiratory symptoms.

HealthDay News — Limited data indicate that paternal exposure to antiseizure medications (ASMs) at conception is unlikely to pose any major risk for adverse outcomes for offspring, according to a ...

BMA discharge also associated with increases in subsequent emergency department visits and unplanned hospital readmissions.

Primary end point was met, with overall response for 74, 67, and 50 percent receiving axatilimab 0.3 mg, 1 mg, and 3 mg per kilogram of body weight ...

HealthDay News — For patients with hereditary hemorrhagic telangiectasia (HHT), pomalidomide yields a significant reduction in epistaxis severity, according to a study published in the September 19 ...

The Food and Drug Administration (FDA) has expanded the approval of Bimzelx ® (bimekizumab-bkzx) to include 3 new indications. In addition to plaque psoriasis, Bimzelx, a humanized interleukin-17A and ...